ATE299496T1 - Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten - Google Patents
Pyridiniumverbindungen zur behandlung von age- relatierten krankheitenInfo
- Publication number
- ATE299496T1 ATE299496T1 AT01201057T AT01201057T ATE299496T1 AT E299496 T1 ATE299496 T1 AT E299496T1 AT 01201057 T AT01201057 T AT 01201057T AT 01201057 T AT01201057 T AT 01201057T AT E299496 T1 ATE299496 T1 AT E299496T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- treatment
- age
- discloses
- related diseases
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 238000002845 discoloration Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201057A EP1243581B1 (de) | 2001-03-21 | 2001-03-21 | Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten |
| JP2001081819A JP4471141B2 (ja) | 2001-03-21 | 2001-03-22 | 老化関連及び糖尿病脈管合併症の管理のための新規化合物、その製造方法及び治療的使用 |
| CA002341949A CA2341949C (en) | 2001-03-21 | 2001-03-23 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses |
| CNB01112413XA CN1148351C (zh) | 2001-03-21 | 2001-03-30 | 用于治疗脉管并发症的化合物,其制备方法及治疗应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE299496T1 true ATE299496T1 (de) | 2005-07-15 |
Family
ID=27427687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01201057T ATE299496T1 (de) | 2001-03-21 | 2001-03-21 | Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1243581B1 (de) |
| JP (1) | JP4471141B2 (de) |
| CN (1) | CN1148351C (de) |
| AT (1) | ATE299496T1 (de) |
| CA (1) | CA2341949C (de) |
| DE (1) | DE60111919T2 (de) |
| DK (1) | DK1243581T3 (de) |
| ES (1) | ES2243389T3 (de) |
| HK (1) | HK1045996B (de) |
| PT (1) | PT1243581E (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2010135524A (ru) * | 2008-01-25 | 2012-02-27 | Торрент Фармасьютикалз Лтд. (In) | Фармацевтические комбинации |
| JP2012508781A (ja) * | 2008-11-17 | 2012-04-12 | テヒニシェ ウニヴェルズィテート ミュンヘン | 糖尿病の治療又は予防に使用されるピリミジニウム誘導体 |
| CA2764232A1 (en) * | 2009-05-07 | 2010-11-11 | Torrent Pharmaceuticals Limited | Novel heterocyclic compounds |
| MX387639B (es) | 2015-04-08 | 2025-03-18 | Torrent Pharmaceuticals Ltd | Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base. |
| EP3280711A1 (de) | 2015-04-08 | 2018-02-14 | Torrent Pharmaceuticals Limited | Neuartige pyridinverbindungen |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH335521A (de) * | 1955-06-02 | 1959-01-15 | Cilag Ag | Verfahren zur Herstellung neuer quaternärer Salze |
| JPH0232006A (ja) * | 1988-07-21 | 1990-02-01 | Shiseido Co Ltd | 皮膚外用剤 |
| JP2817219B2 (ja) * | 1988-09-08 | 1998-10-30 | 武田薬品工業株式会社 | カルバジン酸誘導体、その製造法及び製剤 |
| JPH08175995A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 糖化蛋白変成物質生成阻害剤 |
| CN1142778C (zh) * | 1995-01-18 | 2004-03-24 | 奥尔顿有限公司 | 噻唑鎓化合物用于预防和逆转高级糖基化终产物形成的用途 |
| US6228858B1 (en) * | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
| AU724319B2 (en) * | 1996-05-08 | 2000-09-14 | Alteon Inc. | Substituted imidazolium salts and their use for the inhibition of protein ageing |
| EP0998283A1 (de) * | 1997-04-04 | 2000-05-10 | Smithkline Beecham Corporation | Calcilytische verbindungen |
| JPH11106352A (ja) * | 1997-08-08 | 1999-04-20 | Chugai Pharmaceut Co Ltd | 糖尿病合併症治療剤 |
| JPH11292881A (ja) * | 1998-04-02 | 1999-10-26 | Shionogi & Co Ltd | １Ｈ−ピロロ［３，２−ｃ］ピリジニウム誘導体 |
| EP1222171B1 (de) * | 1999-10-06 | 2004-02-25 | Torrent Pharmaceuticals Ltd | Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen |
| CN1329597A (zh) * | 1999-10-06 | 2002-01-02 | 托伦脱药品有限公司 | 治疗糖尿病及衰老相关性血管性并发症的吡啶鎓衍生物 |
| HUP0104832A2 (en) * | 2001-10-19 | 2003-08-28 | Torrent Pharmaceuticals Ltd | Cosmetic composition and method |
-
2001
- 2001-03-21 DK DK01201057T patent/DK1243581T3/da active
- 2001-03-21 DE DE60111919T patent/DE60111919T2/de not_active Expired - Lifetime
- 2001-03-21 AT AT01201057T patent/ATE299496T1/de active
- 2001-03-21 ES ES01201057T patent/ES2243389T3/es not_active Expired - Lifetime
- 2001-03-21 EP EP01201057A patent/EP1243581B1/de not_active Expired - Lifetime
- 2001-03-21 PT PT01201057T patent/PT1243581E/pt unknown
- 2001-03-22 JP JP2001081819A patent/JP4471141B2/ja not_active Expired - Fee Related
- 2001-03-23 CA CA002341949A patent/CA2341949C/en not_active Expired - Lifetime
- 2001-03-30 CN CNB01112413XA patent/CN1148351C/zh not_active Expired - Lifetime
-
2002
- 2002-10-17 HK HK02107559.6A patent/HK1045996B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2341949A1 (en) | 2002-09-23 |
| EP1243581B1 (de) | 2005-07-13 |
| PT1243581E (pt) | 2005-11-30 |
| DE60111919T2 (de) | 2006-04-20 |
| HK1045996A1 (en) | 2002-12-20 |
| CN1148351C (zh) | 2004-05-05 |
| ES2243389T3 (es) | 2005-12-01 |
| JP4471141B2 (ja) | 2010-06-02 |
| JP2002275158A (ja) | 2002-09-25 |
| HK1045996B (en) | 2006-02-03 |
| CN1377880A (zh) | 2002-11-06 |
| CA2341949C (en) | 2005-10-11 |
| DE60111919D1 (de) | 2005-08-18 |
| EP1243581A1 (de) | 2002-09-25 |
| DK1243581T3 (da) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE508738T1 (de) | System zur beabstandeten abgabe von arzneimitteln | |
| Esper et al. | The effect of two phototherapy protocols on pain control in orthodontic procedure—a preliminary clinical study | |
| MXPA02003495A (es) | Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos. | |
| BR9906813A (pt) | Método para administração de insulina aspb28- humana | |
| EP1064000A4 (de) | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen | |
| MXPA04011612A (es) | Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo. | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| CA2503810A1 (en) | Therapeutic agent for fibromyalgia | |
| AR032065A1 (es) | Derivados de glucopiranosiloxipirazol y composicion farmaceutica | |
| ATE92762T1 (de) | Medikamente. | |
| DE60111919D1 (de) | Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten | |
| HK1044336A1 (zh) | 治疗糖尿病及衰老相关性血管性并发症的吡啶衍生物 | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| RU2001118854A (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний | |
| AU3401093A (en) | Therapeutic agent for threatened abortion | |
| RU96115219A (ru) | Способ лечения больных сахарным диабетом | |
| BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos | |
| BR0104586A (pt) | Método para tratamento de neurodegeneração | |
| RU2267335C1 (ru) | Способ комбинированной анальгезии у пожилых пациентов после операций на тазобедренном суставе и бедре | |
| DE502004011874D1 (de) | Flupirtine-präparat zur behandlung von neurodegeneetes mellitus | |
| RU2002109173A (ru) | Способ лечения дистрофических заболеваний сетчатой оболочки глаза | |
| MC2203A1 (fr) | Medicament contre la cryptosporidiose | |
| RU2002112800A (ru) | Способ лечения диабетической ретинопатии | |
| RU2001125198A (ru) | Способ щадящей терапии опухолевых заболеваний | |
| ATE406172T1 (de) | Verwendung von löslichem cd14 zur behandlung von erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1243581 Country of ref document: EP |